Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

5-Amino-1MQ / 5-Amino-1-methylquinolinium iodide | NNMT Inhibitor Toxicology and Research Laboratory Handling Precautions

Research Use Only Notice: This article is intended only for qualified laboratory research personnel. It summarizes published preclinical and laboratory research information related to 5-Amino-1MQ (commonly supplied as 5-amino-1-methylquinolinium iodide) as an NNMT inhibitor research tool.

It is not human safety information, not a usage guide for non-research settings, and not medical, clinical, veterinary, cosmetic, dietary, or personal-use guidance. All discussion is limited to published or controlled in vitro assays and laboratory animal model research conducted under institutional oversight.

Compound Identity and Article Scope

5-Amino-1MQ is commonly discussed in the nicotinamide N-methyltransferase literature as 5-amino-1-methylquinolinium, a small-molecule NNMT inhibitor rather than a peptide. The commonly supplied research form is 5-amino-1-methylquinolinium iodide (NNMTi).

Therefore, peptide-specific parameters such as amino-acid sequence, peptide chain length, peptide molecular formula, and peptide purity conventions are not applicable to this compound. For peptide materials, laboratory topics such as peptide reconstitution for laboratory research and peptide dosage calculation for research may be relevant, but they should not be transferred to 5-Amino-1MQ without compound-specific validation.

5-Amino-1MQ / 5-Amino-1-methylquinolinium iodide

Peptide-specific purity categories and sequence-based peptide specifications are not applicable; purity should instead be interpreted using small-molecule analytical specifications such as HPLC, LC-MS, NMR, residual solvent, and water-content data where available.[1]

The free quinolinium cation is listed by PubChem as 5-Amino-1-methylquinolinium, molecular formula C10H11N2+, and molecular weight 159.21 g/mol. The commonly referenced iodide salt NNMTi is listed separately as C10H11IN2, molecular weight 286.11 g/mol, CAS Registry Number 42464-96-0, and PubChem CID 66522933.[1][2]

The U.S. NCATS Global Substance Registration System lists 5-Amino-1-methylquinolinium iodide with CAS No. 42464-96-0 and PubChem identifier 66522933, supporting the need to distinguish the supplied salt form from the free cation when reviewing identity data, molecular weight, and certificate-of-analysis documents.[3]

Because different salt forms, supplier lots, and analytical specifications may exist, any COA interpretation should verify the compound name, salt form, CAS number, molecular formula, molecular weight, analytical identity method, assay or purity method, residual solvent information, water content if tested, storage recommendation, and lot-specific validity date against the actual batch documentation. A generic online product description should not replace the lot-specific COA or safety documentation.

This article focuses on research-context toxicology interpretation and laboratory handling precautions for 5-Amino-1MQ as a small-molecule NNMT inhibitor. It does not establish a complete toxicology profile, does not replace institutional risk assessment, does not replace supplier-provided safety documentation, and does not support any human, veterinary, cosmetic, dietary, household, or personal-use application.

The safety-related interpretation of 5-Amino-1MQ should not begin with assumptions drawn from peptide receptor agonists such as semaglutide as a GLP-1 receptor agonist peptide, amylin-related research agents such as cagrilintide, dietary ingredients, cosmetic ingredients, or clinically developed metabolic agents. The relevant research question is whether intracellular NNMT inhibition produces pathway-specific effects under defined laboratory conditions, or whether broader changes in nicotinamide metabolism, NAD+ availability, SAM-dependent methylation balance, and related biochemical pathways may influence additional cellular systems.[4]

Where published studies do not report a toxicological signal, the correct interpretation is “not reported under the tested experimental conditions,” not “fully excluded.”

This distinction is important because many published studies involving 5-Amino-1MQ were designed primarily to evaluate NNMT-related biological mechanisms or model-specific metabolic endpoints, rather than to serve as dedicated toxicology programs.

NNMT Biology, Selectivity, and Off-Target Interpretation

NNMT, or nicotinamide N-methyltransferase, catalyzes the N-methylation of nicotinamide using S-adenosyl-L-methionine as the methyl donor, producing N1-methylnicotinamide and S-adenosyl-L-homocysteine. This makes NNMT directly relevant to nicotinamide metabolism, NAD+ salvage biology, and methyl-donor balance.[4]

5-Amino-1MQ was reported in peer-reviewed NNMT inhibitor research as a membrane-permeable small-molecule inhibitor used in adipocyte assays and diet-induced rodent model studies to evaluate NNMT-related metabolic biology under laboratory conditions.[5]

Published selectivity data should be interpreted carefully. Available reports describe 5-Amino-1MQ as selective for NNMT within tested experimental panels, but those panels do not equal a complete off-target safety profile across all methyltransferases, non-methyltransferase proteins, cell types, exposure durations, or intracellular conditions.[5]

The most scientifically cautious interpretation is not that broad off-target inhibition has been proven, but that broader non-target effects cannot be excluded when experiments use high concentrations, long exposure windows, sensitive cell systems, or designs lacking orthogonal NNMT validation.

For research interpretation, the key question is whether the experimental design can distinguish NNMT-mediated effects from broader small-molecule effects. A concentration-response design, vehicle-matched control, target-engagement marker, and parallel genetic or pharmacological validation can strengthen attribution to NNMT biology.

Useful target-engagement readouts may include reduced 1-methylnicotinamide formation, changes in nicotinamide-related metabolites, and confirmation that the selected cellular or tissue model expresses NNMT at a level relevant to the experimental question.[5]

Researchers should be cautious when interpreting effects that appear only at high concentrations, especially if those effects are accompanied by reduced cell viability, stress-response signatures, broad transcriptional disruption, or vehicle-sensitive assay behavior. In those cases, the data may still be scientifically useful, but it should not be described as exclusively NNMT-mediated without additional evidence.

Complementary approaches such as siRNA-mediated NNMT knockdown, shRNA-mediated knockdown, CRISPR-based perturbation, or comparison with a structurally distinct NNMT inhibitor can help determine whether an observed phenotype follows NNMT biology rather than an unrelated chemical or solvent-associated effect.

Pathway-Level Toxicology Considerations: NAD+, SAM, and Methylation Balance

The research rationale for NNMT inhibition is connected to the biochemical role of NNMT in nicotinamide methylation and SAM consumption. Because these metabolites participate in broad cellular pathways, pathway-level interpretation should remain cautious even when an experiment reports favorable model-specific endpoints.[4]

NAD+ and SAM changes are not automatically harmful, and they should not be interpreted as toxicological findings by themselves. Their meaning depends on magnitude, duration, cell or tissue context, model design, exposure conditions, and whether functional safety-related endpoints were measured.

A short in vitro exposure in adipocytes is not equivalent to chronic systemic exposure in an animal model, and a model-specific biochemical response is not equivalent to a broad toxicological conclusion. For this reason, NAD+ and SAM observations are best treated first as pathway-engagement data, and only secondarily as safety-relevant information when paired with appropriate monitoring endpoints.

NAD+-Related Signaling Considerations

NAD+ is both a redox cofactor and a signaling-related metabolite used by NAD+-dependent enzyme families such as sirtuins, poly(ADP-ribose) polymerases, CD38, and CD157.[6]

Because NAD+-dependent enzymes are involved in DNA repair, protein deacetylation, stress responses, mitochondrial function, and cellular signaling, NNMT-related changes in NAD+ availability should be interpreted in a pathway-specific manner rather than as a simple beneficial-or-harmful binary.[7]

Published adipocyte research has reported concentration-dependent changes in intracellular nicotinamide-related metabolites after 5-Amino-1MQ exposure, including reduced 1-methylnicotinamide and increased intracellular NAD+ in the tested cell model. These findings should be cited as cell-model observations, not generalized as universal tissue-level or whole-organism safety conclusions.[5]

A cell-based NAD+ change should not be converted into a broad tissue-level or whole-organism safety conclusion unless the specific model, dose design, duration, tissue, analytical method, and endpoint context are clearly reported.

This article intentionally avoids presenting animal administration quantities or operational routes as reusable instructions.

For experiments focused on NAD+-dependent biology, total NAD+ alone may not be sufficient. A stronger design may include NADH, the NAD+/NADH ratio, nicotinamide, 1-methylnicotinamide, PARP-related markers, sirtuin-related acetylation markers, and time-course analysis where scientifically justified.

At present, the defensible conclusion is that NAD+-related changes are important pathway-engagement observations in 5-Amino-1MQ research, but publicly available data do not support broad statements about complete long-term safety, universal pathway neutrality, or suitability outside controlled research use.

SAM, SAH, and Methylation-Balance Considerations

NNMT uses SAM as a methyl donor and generates SAH, so NNMT activity is directly connected to the balance between methyl-donor availability and methylation-product accumulation.[4]

The SAM/SAH ratio is often interpreted as a useful indicator of cellular methylation potential because SAM supports methyl-transfer reactions while SAH can inhibit many methyltransferase reactions.[8]

For that reason, a study reporting increased SAM after NNMT inhibition does not automatically prove increased global methylation activity across the genome or proteome. The biological meaning depends on the cell or tissue model, enzyme class, substrate availability, baseline methylation state, exposure duration, and whether SAH changes in parallel.

Experimental literature on excess SAM also supports the idea that methylation balance is not governed by SAM alone; high SAM availability can trigger compensatory or context-dependent metabolic responses rather than simply increasing all methylation reactions in a linear manner.[9]

For methylation-focused NNMT studies, stronger experimental designs may include SAM, SAH, SAM/SAH ratio, nicotinamide, 1-methylnicotinamide, NAD+, global DNA methylation, locus-specific DNA methylation, histone methylation markers, RNA expression profiling, and tissue-specific analysis where relevant.

The safest current interpretation is that methylation-related concerns are biologically plausible and relevant to study design, but they are not established as consistent toxicological findings for 5-Amino-1MQ under all published preclinical conditions.

Published Rodent Model Observations and Their Limits

Published rodent studies involving 5-Amino-1MQ have largely been designed as metabolic-model or mechanism-oriented studies, not as full toxicology packages. This distinction should be preserved throughout any safety-related article about the compound.

In the original NNMT inhibitor research literature, 5-Amino-1MQ was evaluated in cultured adipocytes and diet-induced mouse models to study NNMT-related metabolic biology, including adiposity-related and lipid-related endpoints under defined experimental conditions.[5]

A later Scientific Reports study evaluated 5-amino-1-methylquinolinium in diet-induced obese mice combined with a diet switch and focused on microbiome and adipose-tissue metabolite patterns. This further illustrates that published animal-model work is often endpoint-specific rather than a comprehensive toxicology assessment.[10]

These model observations should be read conservatively. The absence of a consistently reported severe acute toxicological signal in published rodent model contexts is reassuring only within the tested models, study durations, exposure conditions, animal characteristics, and reported endpoints.

Such observations do not prove that 5-Amino-1MQ lacks organ-specific, long-duration, reproductive, developmental, hematological, immunological, genotoxic, or broader off-target risks. Many of these domains have not been examined or have not been reported with sufficient detail in the publicly available 5-Amino-1MQ literature.

Model-specific changes in body-mass or adiposity endpoints require careful interpretation. This is especially important when comparing NNMT inhibitor research with peptide-centered metabolic research topics such as tirzepatide and semaglutide or AOD9604.

In high-fat-diet rodent models, changes in body mass or adipose-tissue measurements may reflect the experimental metabolic endpoint being studied, but safety interpretation is stronger when paired with food intake, body composition, activity, general observations, serum chemistry, hematology, organ weights, and histopathology.

Liver-related observations also require context. Reduced liver weight or reduced steatosis-associated features in a diet-induced model should not be interpreted as proof of broad hepatic safety unless supported by appropriate histological assessment, serum chemistry, inflammatory markers, and study-duration-specific monitoring.

Similarly, if a study reports only limited renal chemistry markers, those data should not be treated as a substitute for kidney histopathology, urinalysis, or longer-duration renal monitoring. These limitations do not invalidate the published model studies; they define the boundary of what can reasonably be concluded from them.

The most important unresolved safety-related research gaps include long-duration exposure, broader dose-response toxicology, sex-specific effects, reproductive and developmental endpoints, hematology, immune monitoring, genotoxicity assessment, and comprehensive off-target profiling across methyltransferase and non-methyltransferase targets.

Any laboratory animal research involving 5-Amino-1MQ should be conducted under approved institutional protocols and should follow applicable animal-care and reporting standards, including the Guide for the Care and Use of Laboratory Animals and transparent reporting principles such as ARRIVE 2.0 where relevant.[11][12]

This article intentionally does not provide animal dose conversion, injection technique, administration route instructions, or any operational animal-use protocol. Published laboratory animal protocols must not be repurposed as human, veterinary, household, or personal-use instructions.

Laboratory Handling Precautions

For qualified laboratory personnel handling 5-Amino-1MQ in research settings, standard institutional chemical hygiene procedures for small-molecule research chemicals should be followed. This includes reviewing the lot-specific supplier safety documentation, institutional risk assessment, and applicable chemical waste-disposal requirements before beginning work.[13]

Handling precautions should distinguish between dry compound, concentrated stock solution, diluted working solution, contaminated consumables, and chemical waste. Each form may have a different practical handling risk depending on concentration, solvent, container, and exposure route within the laboratory environment.

For powder handling, researchers should minimize dust generation, avoid skin and eye contact, avoid inhalation, and use appropriate containment and personal protective equipment according to the institution’s chemical hygiene plan.

For in vitro laboratory stock preparation only, 5-Amino-1MQ may be prepared according to supplier solubility information, lot-specific documentation, and the validated needs of the specific assay. This statement is not a human, veterinary, cosmetic, household, or personal-use preparation instruction.

When DMSO or another organic solvent is used in cell-based research, matched vehicle controls are essential because DMSO itself can affect cell morphology, cell viability, gene expression, and assay readouts depending on concentration, exposure duration, and cell type.[14]

Final solvent concentration should therefore be reported, matched across control and exposure groups, and validated for the specific model system rather than assumed to be biologically inert.

Storage and stability should follow lot-specific supplier documentation unless independently validated by the laboratory. If stability data are not available, researchers should avoid assuming that repeated freeze-thaw cycles, prolonged room-temperature exposure, extended light exposure, or long-term storage in solution have no effect on compound integrity.

For reproducibility, researchers should document compound name, salt form, lot number, preparation date, solvent, stock concentration, storage conditions, freeze-thaw history, final assay concentration, vehicle percentage, exposure duration, and analytical confirmation when available.

COA and Quality-Control Interpretation

A certificate of analysis for 5-Amino-1MQ should be interpreted as a laboratory raw-material quality-control document, not as evidence of human safety, veterinary suitability, cosmetic suitability, dietary suitability, or non-research usability.

For this compound, the most important COA items usually include compound name, salt form, CAS number, molecular formula, molecular weight, lot number, assay or purity result, analytical method, identity confirmation method, water content if tested, residual solvents if tested, storage recommendation, and retest or expiration information where provided.

HPLC purity, LC-MS identity confirmation, NMR identity confirmation, or related analytical results can support laboratory material characterization, but they do not establish biological safety, long-duration toxicology, or suitability outside controlled research use.

Purity interpretation should avoid overstatement. A high HPLC area-percent result does not necessarily identify every impurity, does not always quantify inorganic salt content, does not replace residual solvent testing, and does not establish stability after storage or solution preparation.

Because 5-Amino-1MQ may be referenced as either the quinolinium cation or a supplied iodide salt, COA review should verify that the stated molecular formula, molecular weight, and CAS number match the actual supplied form rather than mixing the free cation parameters with the salt-form parameters.[1][2][3]

COA data should not be used to imply that a research compound is a drug, pharmaceutical ingredient, dietary supplement ingredient, cosmetic ingredient, medical raw material, or veterinary material. Quality-control suitability for laboratory assays is not equivalent to safety or effectiveness for any non-research application.

Research Interpretation Checklist

  • Confirm compound identity: Verify whether the material is the free quinolinium cation or a salt form, and match the molecular formula, molecular weight, and CAS number accordingly.
  • Confirm model relevance: Measure or document NNMT expression in the selected cell or tissue model before attributing results to NNMT inhibition.
  • Confirm target engagement: Where feasible, measure 1-methylnicotinamide, nicotinamide, NAD+, SAM, SAH, or related pathway markers.
  • Control for vehicle effects: Match DMSO or other vehicle concentration across all groups and validate vehicle tolerance in the specific assay system.
  • Avoid overextension: Do not convert in vitro or rodent-model observations into human, veterinary, cosmetic, dietary, personal-use, or consumer-facing claims.
  • Use orthogonal validation: Consider genetic NNMT knockdown or comparison with structurally distinct NNMT inhibitors when mechanistic attribution is central to the study.
  • Report limitations clearly: State when a study lacks comprehensive toxicology endpoints, sex-specific analysis, long-duration exposure, reproductive endpoints, hematology, immunology, or genotoxicity assessment.

Summary Interpretation

The most defensible interpretation is that 5-Amino-1MQ is a small-molecule NNMT inhibitor that has been used in published preclinical research models without prominent severe acute toxicological signals described in the cited preclinical model reports under their specific tested conditions. However, the publicly available evidence does not support broad conclusions about complete toxicological safety, long-duration exposure, reproductive or developmental risk, immunological risk, genotoxicity, or suitability for any non-research application.

Its use as a research tool should therefore be accompanied by target-confirmation experiments, pathway-specific metabolite monitoring, appropriate vehicle controls, lot-specific documentation, and safety endpoints matched to the study duration and biological model.

This cautious interpretation prevents overextension of limited preclinical data while preserving the value of 5-Amino-1MQ as a laboratory NNMT inhibition tool for qualified research settings.

References

  1. PubChem. 5-Amino-1-methylquinolinium.
  2. PubChem. NNMTi.
  3. NCATS Global Substance Registration System. 5-Amino-1-methylquinolinium iodide.
  4. UniProtKB. Nicotinamide N-methyltransferase, human NNMT.
  5. Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase. Biochemical Pharmacology.
  6. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends in Cell Biology.
  7. Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology.
  8. Bravo AC, et al. Method optimisation and profiling of one-carbon metabolites including SAM and SAH. Metabolites.
  9. Fukumoto K, et al. Excess S-adenosylmethionine inhibits methylation via catabolism-dependent mechanisms. Nature Communications.
  10. Dimet-Wiley A, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Scientific Reports.
  11. National Research Council. Guide for the Care and Use of Laboratory Animals. NCBI Bookshelf.
  12. Percie du Sert N, et al. The ARRIVE guidelines 2.0. PLOS Biology.
  13. OSHA. Occupational exposure to hazardous chemicals in laboratories, 29 CFR 1910.1450.
  14. Lee H, et al. Evaluation of the effects of dimethyl sulfoxide on morphology, cell viability, mRNA, and protein expression. Scientific Reports.

Research Use Only Disclaimer

Research Use Only: The research-grade materials discussed in this article are intended exclusively for qualified laboratory research purposes and are not approved for human or veterinary use.

This article is provided for informational context regarding published preclinical research literature and laboratory material-quality principles only. It does not constitute medical, clinical, veterinary guidance or treatment advice.